The National Institute for Health and Care Excellence (NICE) has issued technology appraisal guidance which does not recommend the use of sorafenib (Nexavar)for the first and second-line treatment of advanced and/or metastatic renal cell carcinoma, or for the treatment of advanced hepatocellular carcinoma. In the absence of positive NICE technology appraisal guidance, national health service commissioners should make funding decisions based on an assessment of the available evidence and on the basis of an individual patient's clinical circumstances. Where a cancer drug is not routinely funded by the NHS, patients may be able to access it through the Cancer Drugs Fund. A number of patients have received funding for sorafenib through the fund.